Table 1 Characteristics of the cohort and outcomes
76 patients | |
|---|---|
Patient ‘s characteristics | |
Comorbidities, n (%) | |
Obesitya | 29 (38%) |
Hypertension | 32 (42.1%) |
Diabetes | 28 (36.8%) |
Coronary artery disease | 9 (11.8%) |
Dyslipidemia | 16 (21.1%) |
Smoking | 15 (19.7%) |
Immunosuppression | 5 (6.6%) |
Chronic lung disease | 9 (11.8%) |
Chronic kidney disease | 4 (5.3%) |
Number of comorbidities | 0 (0–1) |
Type of ECMO support, n (%) | |
Veno-venous | 75 (98.7%) |
Arteriovenous | 1 (1.3%) |
Cardiac arrest before ECMO, n (%) | 4 (5.3%) |
Outcome | |
ECMO weaning, n (%) | 45 (59.2%) |
ECMO second run, n (%) | 5 (6.6%) |
ECMO-free days at D60 | 14 (0–36.5) |
MV duration | 41 (27.5–54.5) |
Mortality, n (%) | |
Day 28 | 6 (7.9%) |
Day 60 | 29 (38.2%) |
Day 90 | 37 (48.7%) |
Length of stay in ICU, (days) | 47.5 (33–65) |
Length of stay in hospital, (days) | 50 (38–80) |
Complications during ICU stay, n (%) | |
Invasive aspergillosis | 4 (5.3%) |
Viral reactivation | |
CMV | 32 (43.2%) |
Antiviral treatment | 30 (94%) |
HSV | 21 (28.4%) |
Antiviral treatment | 15 (71%) |
Cause of death, n (%) | |
Septic shock | 13 (17.1%) |
Hemorrhagic shock | 12 (15.8%) |
Cardiogenic shock | 1 (1.3%) |
Stroke | 2 (2.6%) |
Multi-organ failure | 3 (3.9%) |
Other | 6 (7.9%) |